DOP2008000018A - Anticuerpos anti-ige - Google Patents
Anticuerpos anti-igeInfo
- Publication number
- DOP2008000018A DOP2008000018A DO2008000018A DO2008000018A DOP2008000018A DO P2008000018 A DOP2008000018 A DO P2008000018A DO 2008000018 A DO2008000018 A DO 2008000018A DO 2008000018 A DO2008000018 A DO 2008000018A DO P2008000018 A DOP2008000018 A DO P2008000018A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- asthma
- ige
- treatment
- methods
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención está relacionada con novedosos anticuerpos humanos dirigidos específicamente contra la inmunoglobulina humana E (anti-IgE). La presente invención también está relacionada con composiciones farmacéuticas y métodos para el tratamiento del asma, en particular asma alérgica, así como otros trastornos donde interviene la IgE que incluyen rinitis alérgica y alergias alimentarias.iones farmacéuticas y métodos para el tratamiento del asma, en particular asma alérgica, así como otros trastornos donde interviene la IgE que incluyen rinitis alérgica y alergias alimentarias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92154607P | 2007-04-02 | 2007-04-02 | |
US875507P | 2007-12-20 | 2007-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2008000018A true DOP2008000018A (es) | 2008-10-15 |
Family
ID=39831518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2008000018A DOP2008000018A (es) | 2007-04-02 | 2008-04-01 | Anticuerpos anti-ige |
Country Status (21)
Country | Link |
---|---|
US (2) | US7867494B2 (es) |
EP (1) | EP2142214A4 (es) |
JP (1) | JP2010532158A (es) |
KR (1) | KR20100018499A (es) |
CN (1) | CN101808661A (es) |
AR (1) | AR065921A1 (es) |
AU (1) | AU2008236765A1 (es) |
BR (1) | BRPI0809677A2 (es) |
CA (1) | CA2682927A1 (es) |
CL (1) | CL2008000935A1 (es) |
DO (1) | DOP2008000018A (es) |
GT (1) | GT200800034A (es) |
IL (1) | IL201156A0 (es) |
MX (1) | MX2009010765A (es) |
PA (1) | PA8775101A1 (es) |
PE (1) | PE20081899A1 (es) |
RU (1) | RU2009140313A (es) |
SG (1) | SG182985A1 (es) |
TW (1) | TW200904470A (es) |
UY (1) | UY30994A1 (es) |
WO (1) | WO2008123999A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5389442B2 (ja) | 2005-09-29 | 2014-01-15 | メディミューン,エルエルシー | 膜Ig特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
DK2853545T3 (en) * | 2008-09-17 | 2016-08-29 | Xencor Inc | Antibody specific for IgE |
MX337723B (es) | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
WO2010122460A1 (en) * | 2009-04-20 | 2010-10-28 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US10017762B2 (en) | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
MX363819B (es) * | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
US9546219B2 (en) | 2012-02-08 | 2017-01-17 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
MX2016002870A (es) | 2013-09-05 | 2017-02-23 | Amgen Inc | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
JP6519913B2 (ja) * | 2015-02-05 | 2019-05-29 | 国立大学法人名古屋大学 | IgE結合性エピトープペプチドの利用 |
US10293059B2 (en) * | 2015-04-09 | 2019-05-21 | Cornell University | Gene therapy to prevent reactions to allergens |
WO2016191246A2 (en) * | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CN107686521B (zh) * | 2016-08-04 | 2021-04-06 | 越海百奥药业(绍兴)有限公司 | 一种人源化抗IgE单克隆抗体 |
JP7127859B2 (ja) | 2016-11-09 | 2022-08-30 | ノース カロライナ ステート ユニバーシティ | キメラタンパク質を用いたアレルギー疾患の治療 |
AU2018205484A1 (en) | 2017-01-06 | 2019-08-01 | Sixal, Inc. | Therapeutic anti-lgE antibodies and methods and compositions thereof |
MA47775A (fr) | 2017-03-14 | 2020-01-22 | Amgen Inc | Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
BR112020019559A2 (pt) | 2018-03-26 | 2021-01-12 | Amgen Inc. | Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células |
AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
WO2021087368A2 (en) * | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Anti-cd45 antibodies and conjugates thereof |
CN113372450A (zh) * | 2020-03-10 | 2021-09-10 | 北京万华生物工程有限公司 | IgE嵌合性双特异性抗体制备及应用 |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
KR102545843B1 (ko) * | 2021-02-24 | 2023-06-20 | 주식회사 세바바이오텍 | 알러지, 아토피 및 가려움 개선용 기능성 소재의 스크리닝 방법 |
AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DK0710719T3 (da) * | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
WO1992021031A1 (en) * | 1991-05-10 | 1992-11-26 | Alain De Weck | PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US6685939B2 (en) * | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU3923293A (en) * | 1992-03-20 | 1993-10-21 | Immunet | Human monoclonal antibodies and methods for human monoclonal antibody production |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2218489A1 (en) * | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
HUP0301085A3 (en) * | 2000-01-14 | 2005-06-28 | Daiichi Seiyaku Co | Novel peptide and screening method by using the same |
EP1461423B1 (en) | 2001-12-03 | 2008-05-14 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
US20050169909A1 (en) * | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
MY164457A (en) * | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
-
2008
- 2008-04-01 PA PA20088775101A patent/PA8775101A1/es unknown
- 2008-04-01 MX MX2009010765A patent/MX2009010765A/es not_active Application Discontinuation
- 2008-04-01 BR BRPI0809677-5A2A patent/BRPI0809677A2/pt not_active IP Right Cessation
- 2008-04-01 EP EP08742484A patent/EP2142214A4/en not_active Withdrawn
- 2008-04-01 CN CN200880010487A patent/CN101808661A/zh active Pending
- 2008-04-01 KR KR1020097022898A patent/KR20100018499A/ko not_active Application Discontinuation
- 2008-04-01 SG SG2012048765A patent/SG182985A1/en unknown
- 2008-04-01 WO PCT/US2008/004286 patent/WO2008123999A2/en active Application Filing
- 2008-04-01 CA CA002682927A patent/CA2682927A1/en not_active Abandoned
- 2008-04-01 GT GT200800034A patent/GT200800034A/es unknown
- 2008-04-01 TW TW097111898A patent/TW200904470A/zh unknown
- 2008-04-01 US US12/080,419 patent/US7867494B2/en not_active Expired - Fee Related
- 2008-04-01 CL CL2008000935A patent/CL2008000935A1/es unknown
- 2008-04-01 AU AU2008236765A patent/AU2008236765A1/en not_active Abandoned
- 2008-04-01 AR ARP080101376A patent/AR065921A1/es not_active Application Discontinuation
- 2008-04-01 PE PE2008000595A patent/PE20081899A1/es not_active Application Discontinuation
- 2008-04-01 DO DO2008000018A patent/DOP2008000018A/es unknown
- 2008-04-01 RU RU2009140313/15A patent/RU2009140313A/ru not_active Application Discontinuation
- 2008-04-01 JP JP2010502126A patent/JP2010532158A/ja not_active Withdrawn
- 2008-04-01 UY UY30994A patent/UY30994A1/es unknown
-
2009
- 2009-09-24 IL IL201156A patent/IL201156A0/en unknown
-
2010
- 2010-11-24 US US12/954,196 patent/US20110064726A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008236765A1 (en) | 2008-10-16 |
KR20100018499A (ko) | 2010-02-17 |
IL201156A0 (en) | 2010-05-17 |
WO2008123999A9 (en) | 2009-12-10 |
GT200800034A (es) | 2010-03-16 |
JP2010532158A (ja) | 2010-10-07 |
US7867494B2 (en) | 2011-01-11 |
CA2682927A1 (en) | 2008-10-16 |
SG182985A1 (en) | 2012-08-30 |
CN101808661A (zh) | 2010-08-18 |
EP2142214A4 (en) | 2012-03-21 |
RU2009140313A (ru) | 2011-05-10 |
PE20081899A1 (es) | 2009-01-26 |
WO2008123999A3 (en) | 2010-06-24 |
TW200904470A (en) | 2009-02-01 |
BRPI0809677A2 (pt) | 2014-10-07 |
CL2008000935A1 (es) | 2008-11-07 |
EP2142214A2 (en) | 2010-01-13 |
WO2008123999A2 (en) | 2008-10-16 |
AR065921A1 (es) | 2009-07-08 |
PA8775101A1 (es) | 2008-11-19 |
UY30994A1 (es) | 2008-11-28 |
MX2009010765A (es) | 2009-10-26 |
US20110064726A1 (en) | 2011-03-17 |
US20090117124A1 (en) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2008000018A (es) | Anticuerpos anti-ige | |
BRPI0818677B8 (pt) | anticorpos que se ligam à il-4 e/ou il-13, composições farmacêuticas compreendendo os referidos anticorpos, e usos dos mesmos | |
ECSP088690A (es) | Anticuerpos para la linfopoyetina estromal timica (tslp) y usos de la misma | |
ECSP099645A (es) | Anticuerpos anti ige apoptóticos | |
ECSP12012309A (es) | Anticuerpos hacia gdf8 humano | |
BR112014018471A2 (pt) | anticorpos anti-ige m1' e métodos para o seu uso | |
BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
CY1119603T1 (el) | Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112016012860A2 (pt) | Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia | |
EA201291034A1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
BRPI0909040B8 (pt) | derivados de azetidina e ciclobutano, seus usos, e composição | |
BR112016013109A2 (pt) | anticorpos de anti-siglec-8 e métodos de seu uso | |
ECSP088751A (es) | Anticuerpos contra la il-22 humana y usos para los mismos | |
IN2015DN00542A (es) | ||
MX2011013061A (es) | Formulaciones oftalmicas de fluticasona y metodos de uso. | |
UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
WO2010135521A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
EA201590568A1 (ru) | Составы, содержащие экстракты растений | |
MX357166B (es) | Anticuerpos que se unen a notum pectinacetilesterasa. | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
BR112013030260A2 (pt) | formulação farmacêutica nasal contendo fluticasona | |
PH12015500822A1 (en) | Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin | |
GT200800048A (es) | Anticuerpos humanos contra il13 y usos terapeuticos |